Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study

This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.

Trial Details

NCT ID
NCT07509450
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • Fecal Microbial Transplant Enema
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Men and women ≥ 18 years of age
  • Diagnosis of the following:
  • Indolent or aggressive B-cell lymphoma eligible for standard or care CAR-T therapy (Cohort A), or
  • Patients with AML or high risk MDS with indication to undergo reduced-intensity conditioning alloSCT, with an available matched related, unrelated,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →